Pulmonology Medical News about Cystic Fibrosis, Triterpenoid CDDO

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Triterpenoid CDDO Limits Inflammation in Preclinical Models of Cystic Fibrosis Lung Disease
Lung Cellular and Molecular Physiology, 08/28/09

Nichols DP et al. – The findings with the synthetic triterpenoids in multiple cell culture models of CF human airway epithelia agree with effects previously described in other disease models (e.g. neoplastic cells). These include the ability to reduce NFkB activation while increasing Nrf2 activity. As these two signaling pathways appear to be pivotal in regulating the net inflammatory response in the CF airway, these compounds are a promising potential anti–inflammatory therapy for CF lung disease.

<< Previous
Long-term complications of medical patients with hospital...

Next >>
Bilobectomy for non-small cell lung cancer: A search for clinical...